B-Cell Prolymphocytic Leukemia Specialist Diagnosis & Treatment Access

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive mature B-cell leukemia defined by the presence of prolymphocytes — large B lymphocytes with a prominent central nucleolus — constituting more than 55% of the circulating lymphoid cells. Chronic lymphocytic leukemia (CLL) has a much smaller percentage of prolymphocytes and is a biologically distinct, usually more indolent disease. B-PLL is far rarer than CLL (accounting for less than 1% of B-cell leukemias) and carries a significantly worse prognosis, particularly because TP53 gene abnormalities — which make the disease resistant to conventional chemotherapy — are present in the majority of cases.

TP53 abnormalities (deletion of chromosome 17p and/or TP53 gene mutations) are present in approximately 50–75% of B-PLL cases. These abnormalities disrupt the p53 tumour suppressor protein, which normally triggers cell death in response to chemotherapy-induced DNA damage. When p53 is disrupted, alkylating agents (chlorambucil, cyclophosphamide) and purine analogues (fludarabine) are essentially ineffective because the leukaemia cells can no longer respond to DNA damage signals. BTK inhibitors (ibrutinib) and venetoclax work through entirely different mechanisms that do not depend on the p53 pathway and remain active in TP53-disrupted B-PLL. TP53 testing must be completed before starting any treatment.

BTK (Bruton's tyrosine kinase) inhibitors — ibrutinib, acalabrutinib, zanubrutinib — block a key signalling protein in the B-cell receptor pathway that B-PLL cells depend on for survival and proliferation. They work through a mechanism entirely independent of the p53 pathway, which is why they are effective even in TP53-disrupted B-PLL where chemotherapy fails. Published case reports and series describe complete remissions in B-PLL with BTK inhibitor therapy. Although ibrutinib is not specifically approved for B-PLL, it is the most widely used treatment for this condition at specialist centres, where it is prescribed off-label.

Venetoclax is an oral BCL-2 inhibitor that blocks a protein (BCL-2) that prevents cancer cells from dying. B-PLL cells, like many aggressive B-cell malignancies, are dependent on BCL-2 for survival. Venetoclax works independently of the p53 pathway, making it appropriate for TP53-disrupted B-PLL. It has shown activity in B-PLL in published case reports. Because venetoclax can cause rapid tumour lysis (sudden release of tumour cell contents into the blood) when started, a careful 5-week dose ramp-up protocol with close monitoring is mandatory — particularly important in B-PLL given the typically very high tumour burden at diagnosis.

Splenectomy (surgical removal of the spleen) or splenic irradiation may provide temporary symptomatic relief from massive, painful splenomegaly and can improve cytopaenias caused by hypersplenism (the spleen trapping blood cells). However, these are palliative measures that do not address the underlying systemic leukemic disease. They may be used as a bridge while waiting for systemic therapy to take effect, or in patients too frail for systemic therapy. The risks of surgical splenectomy (including post-splenectomy infection, bleeding, and thrombotic complications) must be weighed against the potential symptomatic benefit in each individual patient.

Allogeneic stem cell transplantation (allo-SCT) is the only approach with potential for long-term disease control in B-PLL and is recommended for patients who are fit enough — typically under approximately 65–70 years of age with adequate organ function and an available donor — and who achieve complete or deep partial remission with initial targeted therapy. Given the high relapse rate with all non-transplant approaches, allo-SCT in first remission provides the best prospect for durable remission in eligible patients. HLA typing should be performed at or near the time of diagnosis so donor identification can proceed in parallel with initial treatment.

Response to treatment is monitored by serial complete blood counts (tracking lymphocyte count, haemoglobin, and platelets), clinical examination (spleen size), and imaging (CT scan) at regular intervals. Bone marrow examination may be performed to confirm depth of remission, particularly before planned allo-SCT. For patients receiving venetoclax, serial electrolytes and uric acid monitoring during the ramp-up phase are mandatory. Prolymphocyte count on blood film is a useful direct measure of disease activity. Molecular MRD (measurable residual disease) testing by PCR or flow cytometry is increasingly used in clinical trials to assess depth of remission.

Yes. CancerFax supports patients with B-PLL by reviewing blood film morphology, flow cytometry, bone marrow, and molecular panel reports to confirm the diagnosis and TP53/MYC status; identifying BTK inhibitor and venetoclax access pathways; coordinating specialist haematology second opinions from expert centres with rare leukemia experience; facilitating allo-SCT donor identification and transplant centre referrals; and assisting with access to rare B-cell leukemia clinical trials in India, China, and internationally. Please share your medical reports through the CancerFax portal or contact our team to begin.